Minivelle (Estradiol) Patent Expiration, LOE Window & CMS Spending
Minivelle (Estradiol) by Noven: FDA Orange Book core substance LOE 2030-07-04, 4 AB generics, $3.6M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Noven |
| FDA Application & Pathway | N203752 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | 2030-07-04 |
| Last Listed Patent or Exclusivity Date | 2030-07-04 |
| Orange Book Patents (*PED Extensions) | 4 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 4 |
| 2024 CMS Total Public Spend | $3.6M |
| 2024 Medicare Part D Spend | $1.3M |
| 2024 Medicaid Spend | $2.3M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |